ENTA (STOCKS)
Enanta Pharmaceuticals, Inc
$14.250000
+0.120000 (+0.85%)
Prev close: $14.130000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jay R. Luly
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $432.04M
- Employees
- 131
- P/E (TTM)
- -4.45
- P/B (TTM)
- 4.71
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $65.32M |
| Benefits Costs and Expenses | $148.87M |
| Costs And Expenses | $150.67M |
| Nonoperating Income/Loss | $1.80M |
| Operating Expenses | $150.67M |
| Depreciation and Amortization | $4.59M |
| Research and Development | $106.74M |
| Other Operating Expenses | $39.35M |
| Operating Income/Loss | -$85.35M |
| Income/Loss From Continuing Operations After Tax | -$81.89M |
| Income/Loss From Continuing Operations Before Tax | -$83.55M |
| Income Tax Expense/Benefit | -$1.66M |
| Net Income/Loss | -$81.89M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$81.89M |
| Net Income/Loss Available To Common Stockholders, Basic | -$81.89M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.84 |
| Diluted Earnings Per Share | -$3.84 |
| Basic Average Shares | 21,336 |
| Diluted Average Shares | 21,336 |
| Assets | $280.73M |
| Current Assets | $204.34M |
| Noncurrent Assets | $76.40M |
| Fixed Assets | $35.40M |
| Other Non-current Assets | $41.00M |
| Liabilities | $216.02M |
| Current Liabilities | $48.56M |
| Accounts Payable | $1.95M |
| Wages | $6.47M |
| Other Current Liabilities | $40.14M |
| Noncurrent Liabilities | $167.46M |
| Equity | $64.72M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $64.72M |
| Liabilities And Equity | $280.73M |
| Net Cash Flow From Operating Activities | -$19.27M |
| Net Cash Flow From Operating Activities, Continuing | -$19.27M |
| Net Cash Flow From Investing Activities | $40.35M |
| Net Cash Flow From Investing Activities, Continuing | $40.35M |
| Net Cash Flow From Financing Activities | -$26.62M |
| Net Cash Flow From Financing Activities, Continuing | -$26.62M |
| Net Cash Flow | -$5.54M |
| Net Cash Flow, Continuing | -$5.54M |
| Comprehensive Income/Loss | -$82.53M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$82.53M |
| Other Comprehensive Income/Loss | -$641.00K |
| Other Comprehensive Income/Loss Attributable To Parent | -$641.00K |